Exact Sciences’ Colorectal Cancer Test Gets Expanded Indication
The FDA approved Exact Sciences’ noninvasive colorectal cancer screening test, Cologuard, for eligible patients aged 45 years and older.
The at-home diagnostic test’s new indication expands the screening age by five years during a time when incidences of colorectal cancer are rising in patients under 50.
Cologuard is a stool DNA-based colorectal cancer screening test for average-risk individuals. The test uses a biomarker panel, which analyzes a stool sample for 10 DNA markers.